August 3, 2020
Daiichi Sankyo said on July 31 that its first-quarter sales faltered 4.9% year on year to 236.9 billion yen as strong performances from global products including Enhertu (trastuzumab deruxtecan) failed to counter the negative impact of COVID-19 particularly in the...read more